Quantity of eligible sufferers: CDEC talked about the uncertainty in the quantity of clients with reasonably critical to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who're classified as acquiring gentle or average disease can have a significant bleed